6/19/2013 9:38:50 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STOCKHOLM, SWEDEN – June 19, 2013. Athera Biotechnologies AB today announced
that it has entered into an option agreement with Boehringer Ingelheim
International GmbH on a novel preclinical antibody program, whereby Athera
grants to Boehringer Ingelheim an exclusive option to acquire the entire
program. Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Athera’s fully-human monoclonal antibody is intended for the treatment of
patients with cardiovascular disease, who are at an increased risk of secondary
events and death.
Help employers find you! Check out all the jobs and post your resume.
comments powered by